Posts With Tag BTK inhibitor

AstraZeneca's Calquence receives EU approval for untreated MCL, offering new hope with improved survival rates. This report details clinical trial results and market implications.

Discover AstraZeneca's financial report on Calquence's EU approval for untreated CLL, highlighting significant trial results and market potential.